» Articles » PMID: 32808459

Is Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVID-19 Severity?

Overview
Date 2020 Aug 19
PMID 32808459
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence has emerged regarding an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with worse prognosis in elderly male patients with obesity, and blunted growth hormone (GH) secretion represents a feature of this population subgroup. Here, a comprehensive review of the possible links between GH-insulinlike growth factor 1 axis impairment and coronavirus disease 2019 (COVID-19) severity is offered. First, unequivocal evidence suggests that immune system dysregulation represents a key element in determining SARS-CoV-2 severity, as well as the association with adult-onset GH deficiency (GHD); notably, if GH is physiologically involved in the development and maintenance of the immune system, its pharmacological replacement in GHD patients seems to positively influence their inflammatory status. In addition, the impaired fibrinolysis associated with GHD may represent a further link between GH-insulin-like growth factor 1 axis impairment and COVID-19 severity, as it has been associated with both conditions. In conclusion, several sources of evidence have supported a relationship between GHD and COVID-19, and they also shed light upon potential beneficial effects of recombinant GH treatment on COVID-19 patients.

Citing Articles

Risk Factors Involved in the Blood (Leukocyte-Depleted Suspended Red Blood Cells and Plasma) Transfusion During Glioma Operations.

Huang B, Sun J, Yu L, Xiong J J Blood Med. 2025; 16:83-93.

PMID: 40007580 PMC: 11853122. DOI: 10.2147/JBM.S493305.


The Impact of Growth Hormone Treatment on COVID-19 Susceptibility and Severity in Children with Short Stature: A Survey Study with Mendelian Randomization Analysis.

Qiu W, Wang R, Liang L, Sun Y, Zhou R, Wang X Infect Drug Resist. 2024; 17:5675-5684.

PMID: 39720618 PMC: 11668050. DOI: 10.2147/IDR.S483477.


Hypopituitarism and COVID-19.

Carosi G, Cremaschi A, Giavoli C, Ferrante E, Mantovani G Pituitary. 2024; 27(6):925-934.

PMID: 39560821 DOI: 10.1007/s11102-024-01463-3.


Obesity-Associated Hepatic Steatosis, Somatotropic Axis Impairment, and Ferritin Levels Are Strong Predictors of COVID-19 Severity.

Masi D, Gangitano E, Criniti A, Ballesio L, Anzuini A, Marino L Viruses. 2023; 15(2).

PMID: 36851702 PMC: 9968194. DOI: 10.3390/v15020488.


Growth hormone level in COVID-19 patients.

Baykan E, Baykan A, Utlu M, Deve E, Yildiz F, Birdal C North Clin Istanb. 2022; 9(5):470-475.

PMID: 36447588 PMC: 9677050. DOI: 10.14744/nci.2021.90094.


References
1.
Bodart G, Farhat K, Charlet-Renard C, Salvatori R, Geenen V, Martens H . The Somatotrope Growth Hormone-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor-1 Axis in Immunoregulation and Immunosenescence. Front Horm Res. 2017; 48:147-159. DOI: 10.1159/000452913. View

2.
Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M . Serum cytokine levels in GH-deficient children during substitutive GH therapy. Eur J Endocrinol. 2005; 152(2):207-10. DOI: 10.1530/eje.1.01827. View

3.
Felbinger T, Suchner U, Goetz A, Briegel J, Peter K . Recombinant human growth hormone for reconditioning of respiratory muscle after lung volume reduction surgery. Crit Care Med. 1999; 27(8):1634-8. DOI: 10.1097/00003246-199908000-00043. View

4.
Zheng K, Gao F, Wang X, Sun Q, Pan K, Wang T . Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020; 108:154244. PMC: 7166301. DOI: 10.1016/j.metabol.2020.154244. View

5.
Seidell J, Bjorntorp P, Sjostrom L, Kvist H, SANNERSTEDT R . Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990; 39(9):897-901. DOI: 10.1016/0026-0495(90)90297-p. View